Tag: Multiple Myeloma

A personalized genomic cancer vaccine proved feasible to manufacture and was well tolerated in a phase 1 trial, according to researchers. The vaccine, PGV-001, was given to 13 patients with solid tumors or multiple myeloma who had a high risk of recurrence after surgery or autologous stem cell transplant. At last follow-up, four patients were

Researchers from Uppsala University show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma. The reduction is caused by changes in the cancer cells' metabolism. These changes can be used as markers to discriminate whether a patient would respond to treatment

More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in Journal of Clinical Oncology. The study recommends that patients undergo a detailed cardiovascular history before being prescribed carfilzomib and then be monitored with natriuretic peptide testing, an indicator for